94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Alaa Rahhal1*
Tahseen Hamamyh2
Ammar Chapra2Khaled J. Zaza3
Mostafa Najim4Mohammad Hemadneh5
Hazem Faraj5Wael Kanjo5Ahmed Yasin5Haneen Toba5Wafa Mohammed5Mohammad Khair Hamad6
Nawras Al-Tikrety5
Mhd Baraa Habib2
Ahmed Awaisu7Ahmed Mahfouz1Sumaya Alyafei1Abdul Rahman Arabi8
Ashfaq Patel9Mohammed Al-Hijji8,10
- 1Pharmacy Department, Hamad Medical Corporation, Doha, Qatar
- 2Cardiology Department, Hamad Medical Corporation, Doha, Qatar
- 3Anesthesiology, Intensive Care and Perioperative Medicine Department, Hamad Medical Corporation, Doha, Qatar
- 4Internal Medicine Department, Rochester Regional Health, New York, NY, United States
- 5Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar
- 6Endocrinology Department, Hamad Medical Corporation, Doha, Qatar
- 7Department of Clinical Pharmacy and Practice, Qatar University, Doha, Qatar
- 8Interventional Cardiology Department, Hamad Medical Corporation, Doha, Qatar
- 9Heart Failure Department, Hamad Medical Corporation, Doha, Qatar
- 10Department of Medicine, Weill Cornell Medicine, Doha, Qatar
A Corrigendum on
By Rahhal A, Hamamyh T, Chapra A, Zaza KJ, Najim M, Hemadneh M, Faraj H, Kanjo W, Yasin A, Toba H, Mohammed W, Hamad MK, Altikretym N, Baraa Habib M, Awaisu A, Mahfouz A, Alyafei S, Arabi A, Patel A and Al-Hijji M. (2024) Front Cardiovasc Med. 11. doi: 10.3389/fcvm.2024.1383669
In the published article, there was an error in the Funding statement. The authors declared receiving no financial support for the research, authorship, or publication of this article. The correct Funding statement appears below.
Funding
The author(s) declare financial support was received for the research and/or publication of this article. The Medical Research Center at Hamad Medical Corporation provided the publication open-access fees.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: acute coronary syndrome, heart failure, sodium–glucose cotransporter-2 (SGLT-2) inhibitors, HF hospitalization, cardioprotection
Citation: Rahhal A, Hamamyh T, Chapra A, Zaza KJ, Najim M, Hemadneh M, Faraj H, Kanjo W, Yasin A, Toba H, Mohammed W, Hamad MK, Al-Tikrety N, Baraa Habib M, Awaisu A, Mahfouz A, Alyafei S, Arabi AR, Patel A and Al-Hijji M (2025) Corrigendum: Sodium–glucose cotransporter-2 inhibitors improve cardiovascular outcomes post-acute coronary syndrome complicated by acute heart failure. Front. Cardiovasc. Med. 12:1580343. doi: 10.3389/fcvm.2025.1580343
Received: 20 February 2025; Accepted: 24 February 2025;
Published: 5 March 2025.
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
Copyright: © 2025 Rahhal, Hamamyh, Chapra, Zaza, Najim, Hemadneh, Faraj, Kanjo, Yasin, Toba, Mohammed, Hamad, Al-Tikrety, Baraa Habib, Awaisu, Mahfouz, Alyafei, Arabi, Patel and Al-Hijji. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alaa Rahhal, YXJhaGhhbDFAaGFtYWQucWE=